Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach.

ABSTRACT:

Background

Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients.

Materials and methods

We used a commercially available antibody array that includes 656 antibodies to analyse blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with GBM.

Results

We identified 11 plasma proteins that are statistically most strongly associated with the presence of

SUBMITTER: Zupancic K 

PROVIDER: S-EPMC4110082 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature